Beyond Air, Inc. (XAIR) Reports In-Line Q1 EPS, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Beyond Air, Inc. (XAIR) Submits Premarket Approval Application to FDA for LungFit PH to Treat Persistent Pulmonary Hypertension of the Newborn
November 11, 2020 7:31 AM ESTBeyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO (gNO) for the treatment of solid tumors, today announced the submission of a premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for its LungFit PH to treat persistent pulmonary hypertension of the newborn (PPHN). FDA guidelines allow for a 180-day review period for a PMA.
... More
